Clinician beliefs and attitudes about buprenorphine/naloxone diversion
Version of Record online: 11 APR 2013
Copyright © American Academy of Addiction Psychiatry
The American Journal on Addictions
Volume 22, Issue 6, pages 574–580, NovemberߝDecember 2013
How to Cite
Schuman-Olivier, Z., Connery, H., Griffin, M. L., Wyatt, S. A., Wartenberg, A. A., Borodovsky, J., Renner, J. A. and Weiss, R. D. (2013), Clinician beliefs and attitudes about buprenorphine/naloxone diversion. The American Journal on Addictions, 22: 574–580. doi: 10.1111/j.1521-0391.2013.12024.x
- Issue online: 16 OCT 2013
- Version of Record online: 11 APR 2013
- Manuscript Accepted: 22 OCT 2012
- Manuscript Revised: 20 JUN 2012
- Manuscript Received: 12 MAR 2012
Background and Objectives
Concern about diversion of buprenorphine/naloxone (B/N) in the United States may affect prescribing patterns and policy decisions. This study examines addiction treatment clinician beliefs and attitudes regarding B/N diversion.
Participants (n = 369) completed a 34-item survey in 2010 during two national symposia on opioid dependence. We conducted multivariable regression, examining the relationship of perceived danger from B/N diversion with clinician characteristics and their beliefs about B/N treatment and diversion. We compared causal beliefs about diversion among clinicians with and without B/N treatment experience.
Forty percent of clinicians believed that B/N diversion is a dangerous problem. The belief that B/N diversion increases accidental overdoses in the community was strongly associated with perceived danger from B/N diversion.
Conclusions and Scientific Significance
Attitudes and beliefs, not education level, were associated with clinician's perceived danger from B/N diversion. Clinicians with greater B/N patient experience were more likely to believe treatment access barriers are the major cause of B/N diversion. (Am J Addict 2013;22:574–580)